<![CDATA[Signatera ctDNA Test Shows Superior MRD Assessment in Lymphoma ]]>

Data ReadoutpositiveSignateraPositive

AI Analysis

Summary

Natera's Signatera tumor-informed ctDNA test demonstrated superior performance compared to PET/CT imaging for minimal residual disease assessment across B- and T-cell lymphoma subtypes.

Outcome Details

Signatera ctDNA test outperformed standard PET/CT imaging in MRD assessment across B- and T-cell lymphoma subtypes

Importance:6/10

Sentiment:

0.75

oncologyliquid biopsyctDNAMRDlymphomadiagnostic

Related Companies

$NTRA

Read the original article

Published by Cancer Network on September 1, 2026 3:30 PM

Read Original